tbuckley/cabot-search huggingface dataset:
Abstract 1648: Agreement and Disagreement between Contrast-Enhanced Magnetic Resonance Imaging and Nuclear Imaging for Assessment of Myocardial Viability
Authors: Stijntje D Roes, Theodorus A Kaandorp, Maureen M Henneman, Nina Ajmone, Jos J Westenberg, Marcel P Stokkel, Hildo J Lamb, Ernst E van der Wall, Albert de Roos, Jeroen J Bax
Journal: Circulation (2007)

Purpose To determine the agreement between contrast-enhanced MRI (ce-MRI) and nuclear imaging for assessment of viability in patients with severe ischemic LV dysfunction. Methods Patients (n = 25) with severe ischemic LV dysfunction (EF 25 ± 11%) were studied with cine MRI, ce-MRI, 99m Tc-tetrofosmin single photon emission computed tomography (SPECT) and 18 F-FDG SPECT. Using a 17-segment model, each segment was assigned a wall motion score (0: normokinesia to 4: dyskinesia) and a scar score (0: no infarction to 4: 76–100% transmurality). Furthermore, 99m Tc-tetrofosmin and 18 F-FDG segmental tracer uptake was categorized (0: tracer activity &gt; 75% to 3: tracer activity &lt; 25%). Dysfunctional segments were classified into viability patterns assessed with SPECT: normal pattern (normal perfusion and metabolism), mismatch (decreased perfusion, increased metabolism), mild match (mild decrease in perfusion and metabolism), and severe match (severe decrease in perfusion and metabolism). Difference in scar score between viability patterns was assessed using one-way ANOVA analysis. Results Of all analyzed segments (n = 425), 289 (68%) showed abnormal wall motion. Mean scar score was 0.3±0.7 in segments with a normal viability pattern, 1.0±1.2 in mismatch, 1.3±1.0 in mild match and 2.7±1.0 in severe match (p&lt;0.001 between all patterns, NS between mismatch and mild match). The relation between MRI and SPECT is presented in Figure 1 . Conclusion Agreement between MRI and nuclear imaging for assessment of viability is high in segments with transmural scar on ce-MRI. However, non-enhanced tissue on ce-MRI can represent normal or jeopardized (perfusion-metabolism mismatch) myocardium.
Ki-4(scFv)–ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice
Authors: Stefan Barth, Michael Huhn, Bärbel Matthey, Samir Tawadros, Roland Schnell, Timo Schinköthe, Volker Diehl, Andreas Engert
Journal: Blood (2000)
Screening for Hemochromatosis: Recommendation Statement
Authors: Ned Calonge, Diana B. Petitti, Thomas G. DeWitt, Leon Gordis, Kimberly D. Gregory, Russell P Harris, Kenneth W. Kizer, Michael L. LeFevre, Carol Loveland-Cherry, Lucy N. Marion, Virginia A. Moyer, Judith K. Ockene, George F. Sawaya, Albert L. Siu, Steven M. Teutsch, Barbara P. Yawn
Journal: Annals of Internal Medicine (2006)

This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendation on screening for hemochromatosis and the supporting scientific evidence. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and on the USPSTF Web site (www.preventiveservices.ahrq.gov). The USPSTF is redesigning its recommendation statement in response to feedback from primary care clinicians. The USPSTF plans to release, later in 2006, a new, updated recommendation statement that is easier to read and incorporates advances in USPSTF methods. The recommendation statement in this paper is an interim version that combines existing language and elements with a new format. Although the definitions of grades remain the same, other elements have been revised. *For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.
CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins
Authors: Martin Carroll, Sayuri Ohno-Jones, Shu Tamura, Elisabeth Buchdunger, Jürg Zimmermann, Nicholas B. Lydon, D. Gary Gilliland, Brian J. Druker
Journal: Blood (1997)
Abstract 3009: Major Subgroup Analyses from the FINESSE Trial: Evaluation of Abciximab + Half -Dose Reteplase, Abciximab Alone, or Placebo for Facilitation of Primary PCI for ST Segment Elevation MI
Authors: Michal Tendera, Klinika I Katedra, Stephen G Ellis, A.J. van Boven, Mark A de Belder, Gilles Montalescot, Petr Widimsky, Luc Janssens, H.R. Andersen, Jerzy Adamus, Jan Z Peruga, Maciej Kosimder, Amadeo Betriu, Paul Armstrong, Bruce Brodie, Howard C Herrmann, Elliot S Barnathan
Journal: Circulation (2007)

Introduction: Whereas primary PCI is the preferred reperfusion strategy for acute ST elevation MI if performed promptly, treatment delays are common. Methods: We tested the hypothesis in a randomized placebo-controlled double-blind trial of 2452 subjects from 20 countries that early pharmacologic therapy with half dose reteplase and abciximab, followed by PCI would improve the outcome in ST elevation MI patients presenting within 6 hours of symptom onset with anticipated first medical contact to catheterization time of 1– 4 hours, relative to patients receiving abciximab at the time of primary PCI; with a third randomized arm of early abciximab to better evaluate the contribution of reteplase to the combination therapy. The primary study endpoint was a composite of all cause mortality, ventricular fibrillation beyond 48 hours, cardiogenic shock or heart failure requiring re-hospitalization or an emergency room visit within 90 days. A major secondary endpoint was % ST segment resolution (&gt;70%) 60 –90 min after randomization. Final patient enrollment was completed December 30, 2006, and 90 day follow up results will be available fall 2007. Results: Enrollment demographics are as follows: mean age = 62 years (16% ≥75), 26% female, 10% Killip II-IV, 11% prior MI, 16% diabetics, 48% anterior MI and 61% enrolled ≤ 3h after symptom onset. The median times from symptom onset to randomization, and randomization to first balloon inflation by tertiles were 1.5, 2.6, and 4.4 hours and 1.2, 1.8, and 2.6 hours, respectively. Pre specified subgroup analyses for the primary and major secondary study endpoints included time from symptom onset to randomization (≥3 vs &gt;3 hours), randomization time to first balloon inflation (by tertiles), Killip Class (I vs II-IV), gender, age (&lt;75 vs ≤75 years), history of prior MI, diabetes, and anterior vs non-anterior MI. Conclusion: The findings from these analyses will supplement the primary study results from this, the largest randomized trial of facilitated angioplasty, to help define the proper management of this important group of high-risk patients.
Predictors of cognitive change in middle-aged and older adults with memory loss
Authors: G W Small, A La Rue, S Komo, A Kaplan, M A Mandelkern
Journal: American Journal of Psychiatry (1995)

Previous longitudinal studies of age-related memory loss have focused on objective neuropsychological measures that predict subsequent cognitive change, yet brain metabolic function, self-perception of memory loss, and other measures may also be sensitive indicators of cognitive change. To determine such baseline predictors of change, the authors made longitudinal assessments of middle-aged and older adults with memory loss.Forty-two persons (mean age = 60 years, range = 43-81) with memory complaints received comprehensive baseline assessments, including subjective neuropsychological measures, objective measures of visual-spatial memory (the Benton Visual Retention Test) and verbal memory (the Buschke-Fuld Selective Reminding Test), and positron emission tomography scans to determine neocortical glucose metabolism. At an average follow-up of 3 years, the objective neuropsychological measures were again used to quantify the degree of cognitive change.Multiple regression analyses indicated that parietal asymmetry, sex of the subject, and baseline visual-spatial memory score were significant predictors of change in visual-spatial memory; level of education and baseline verbal memory score predicted change in verbal memory. Other neocortical asymmetry scores, age, family history of Alzheimer's disease, cerebral atrophy, and self-ratings of use of mnemonics were not significant predictors of change.Measures of cerebral metabolism, objective memory performance, sex, and education may predict subsequent cognitive change in middle-aged and older persons with memory loss. Also, the parietal asymmetry found in persons with questionable dementia that progresses to probable Alzheimer's disease may be present very early in the course of age-related cognitive decline.
Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope™): Case Matched Analysis
Authors: Maria J.G.T. Vehreschild, J. Janne Vehreschild, Francisco M Marty, John R Perfect, Luis Ostrosky-Zeichner, Galia Rahav, Bernhardt Zeiher, Misun Lee, Rochelle Maher, Clint Lovell, Marc Engelhardt, Oliver A Cornely
Journal: Blood (2014)
阿司匹林、布洛芬与心肌梗死后死亡率：回顾性队列研究
Authors: JepthaPCurtis, YongfeiWang, EdwardLPortnay, FrederickAMasoudi, EdwardPHavranek, HarlanMKrumholz, 王春宁, 高润霖
Journal: BMJ (2004)

观察性研究和在体试验结果引起人们的关注：服用阿司匹林的心脏保护作用可被布洛芬(一种可竞争性抑制血小板上阿司匹林结合位点的非甾体类抗炎药)所阻断。我们旨在确定心肌梗死后出院患者服用阿司匹林及布洛芬是否与增加死亡危险有关。
指南——早期乳腺癌（包括局部晚期）的诊断和治疗：NICE指南概要
Authors: Adrian, Harnett, James, Smallwood, Victoria, Titshall, Andrew, Champion, 李俏, 徐兵河
Journal: BMJ (2009)

为什么要阅读本概要？ 乳腺癌是女性最常见的癌症，在英格兰和威尔士，每年有超过40500例患者被诊断为乳腺癌。尽管受益于筛查和治疗的进步，以年龄标准化的死亡率正稳步下降，但在英格兰和威尔士，每年仍有10900人死于此病，同时社会和情感影响巨大。本文总结了来自英国国家卫生和临床医疗优选研究所（National Institute for Health and Clinical Excellence，NICE）关于早期和局部晚期乳腺癌诊断和治疗的最重要、最新推荐。
Abstract 2958: Novel Role of Protein Inhibitor of Activated Stat1 (PIAS1) as a Substrate of P90rsk in Diabetic (DM) Cardiomyopathy via Small Ubiquitin-related Modification of ERK5 Kinase (ERK5-sumoylation)
Authors: Changhoon Woo, Tetsuro Shishido, Eugene Chang, Hiroki Takahashi, Yan Lu, Carolyn McClain, Jun-ichi Abe
Journal: Circulation (2009)

Post-myocardial infarction (MI) left ventricular (LV) function is worse in DM patients, but the exact mechanism remains unclear. After extensive survey of activated kinases in DM, we reported the s...
Esophageal Pressure in Acute Lung Injury
Authors: Ricardo Valentini, Pablo Rodriguez, Ignacio Bonelli
Journal: New England Journal of Medicine (2009)

observed an improvement in oxygenation in patients with acute lung injury that was man -aged by estimating transpulmonary pressure, there was an extrapulmonary (i.e., abdominal) cause of the acute respiratory distress syndrome (ARDS) in a high proportion of patients in their study (39%). To our knowledge, this feature has not been observed in any previously published ran -domized studies involving patients with ARDS.
Abstract 337: Activation of Myocardial AMP-activated Protein Kinase by Metformin Prevents Progression of Heart Failure in Dogs; Involvement of eNOS Activation
Authors: Hideyuki Sasaki, Hiroshi Asanuma, Masashi Fujita, Hiroyuki Takahama, Masanori Asakura, Jiyoong Kim, Tetsuo Minamino, Seiji Takashima, Shoji Sanada, Shin Ito, Kyungduk Min, Kazuo Komamura, Naoki Mochizuki, Masafumi Kitakaze
Journal: Circulation (2008)

Background; Several studies have shown that metformin activates AMP-activated protein kinase (AMPK), which mediates potent cardioprotection against ischemia-reperfusion injury. AMPK is also activated in experimental failing myocardium, suggesting that activation of AMPK is beneficial for the pathophysiology of heart failure. We investigated whether metformin prevents oxidative stress-induced cell death in rat cardiomyocytes and attenuates the progression of heart failure in dogs. Methods and Results; The treatment with metformin (10 μmol/L) protected the rat cultured cardiomyocytes against cell death due to H 2 O 2 exposure (50 μmol/L) as indicated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), TUNEL staining, and flow cytometry. These effects were blunted by an AMPK inhibitor, compound-C (20 μmol/L), suggesting that the activation of AMPK decreased the extent of apoptosis-induced cell death due to H 2 O 2 exposure. Continuous rapid ventricular pacing (230/min for 4 weeks) in dogs caused heart failure and the treatment with metformin (100 mg/kg/day PO, n=8) decreased left ventricular (LV) end-diastolic dimension (32.8±0.4 vs. 36.5±1.0 mm, p&lt; 0.01) and pressure (11.8±1.1 vs. 22±0.9 mmHg, p&lt; 0.01), and increased LV fractional shortening (18.6±1.8 vs. 9.6±0.7 %, p&lt; 0.01) along with enhanced phosphorylation of AMPK and the decreased the number of TUNEL-positive cells of the LV myocardium compared with the vehicle group (n=8). Interestingly, metformin increased the protein and mRNA levels of endothelial nitric oxide synthase of the LV myocardium and plasma nitric oxide levels. Metformin improved the plasma insulin resistance without increased myocardial GLUT-4 translocation. Furthermore, the subcutaneous administration of AICAR (50 mg/kg/every other day), another AMPK activator mediated the equivalent effects to metformin, strengthening the pivotal role of AMPK in reduction of apoptosis and prevention of heart failure. Conclusions; Activation of myocardial AMPK attenuated the oxidative stress-induced cardiomyocyte apoptosis and prevented the progression of heart failure in dogs, along with eNOS activation. Thus, metformin or AICAR may be applicable as a novel therapy for heart failure.
Introduction to Medical Biometry and Statistics
Authors: J. H. Watkins
Journal: JAMA (1941)

PROF. RAYMOND PEARL has had many years' experience in teaching the principles of biometric methods to biologists and medical men, and the present book is essentially an account of the mode of treatment of this subject which he has found most successful in the School of Biometry at Johns Hopkins University. It is the result of an attempt to make available a simple exposition of the elementary principles of the subject for those biologists and medical men who have had no special mathematical training, and yet find it necessary to use modern biometric methods in their work.
Intracellular Distribution of Enzymes. VII. The Distribution of Nucleic Acids and Adenosinetriphosphatase in Normal Mouse Liver and Mouse Hepatoma
Authors: Walter C. Schneider, George H. Hogeboom, Helen E. Ross
Journal: JNCI Journal of the National Cancer Institute (1950)

Journal Article Intracellular Distribution of Enzymes. VII. The Distribution of Nucleic Acids and Adenosinetriphosphatase in Normal Mouse Liver and Mouse Hepatoma Get access Walter C. Schneider, Walter C. Schneider Search for other works by this author on: Oxford Academic PubMed Google Scholar George H. Hogeboom, George H. Hogeboom Search for other works by this author on: Oxford Academic PubMed Google Scholar Helen E. Ross Helen E. Ross National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 4, February 1950, Pages 977–982, https://doi.org/10.1093/jnci/10.4.977 Published: 01 February 1950 Article history Received: 12 January 1950 Published: 01 February 1950
Effects of Sperm Protamine on Human Cervical Epithelial Cells and BHK 21 Cells <i>in Vitro</i>
Authors: P W French, M Coppleson, B L Reid
Journal: Journal of the Royal Society of Medicine (1987)

The addition of protamine, of both human and animal origin, to cultures of epithelial and fibroblastic cells has demonstrated that this component of sperm proteins may be capable of bringing about neoplastic transformation in vitro.
Lead Poisoning and Anemia Associated with Use of Ayurvedic Medications Purchased on the Internet — Wisconsin, 2015
Authors: Jon Meiman, Robert Thiboldeaux, Henry Anderson
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

On April 30, 2015, the Wisconsin Division of Public Health (WDPH) was notified by a local health department of an elevated blood lead level (BLL) in a female patient aged 64 years. All Wisconsin laboratories are required to provide BLL testing results performed on any state resident to WDPH, and WDPH and local health departments are statutorily mandated to investigate any single BLL ≥20 µg/dL or BLLs that are persistently ≥15 µg/dL. Review of medical records revealed that the patient had developed progressive fatigue and shortness of breath during a period of multiple weeks that prompted inpatient medical evaluation. Hemoglobin level was 8.3 g/dL (normal range for age and sex of patient = 12.5-15.0 g/dL), and peripheral blood smear showed normochromic, normocytic red blood cells with basophilic stippling. A BLL was obtained and found to be 85.8 µg/dL. Urine toxic metals tests revealed mercury and aluminum levels in the normal range. Combined methylated and inorganic urine arsenic levels were slightly elevated at 53.3 µg/L (normal = <18.9 µg/L). The patient was discharged for outpatient lead chelation therapy with oral meso-2,3-dimercaptosuccinic acid.
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report
Authors: E Vilmer, S Suciu, A Ferster, Y Bertrand, H Cavé, A Thyss, Y Benoit, N Dastugue, M Fournier, G Souillet, A-M Manel, A Robert, B Nelken, F Millot, P Lutz, X Rialland, F Mechinaud, P Boutard, C Behar, J-M Chantraine, E Plouvier, G Laureys, P Brock, A Uyttebroeck, G Margueritte, D Plantaz, L Norton, N Francotte, J Gyselinck, C Waterkeyn, G Solbu, N Philippe, J Otten
Journal: Leukemia (2000)
The NIMH Depression Awareness, Recognition, and Treatment Program: structure, aims, and scientific basis
Authors: Darrel A. Regier, Robert M. Hirschfeld, Frederick K. Goodwin, Jack D. Burke, Joyce B. Lazar, Lewis L. Judd
Journal: American Journal of Psychiatry (1988)

Unrecognized, untreated, and undertreated depressive disorders extract an inordinate human and economic cost, despite the availability of an extensive array of effective clinical interventions. To enhance the availability and quality of care, the National Institute of Mental Health launched the Depression Awareness, Recognition, and Treatment Program, a multiphase information and education program designed to alert health professionals and the general public to the fact that depressive disorders are common, serious, and treatable. The authors review the development of this program, describing the professional education efforts it supports in anticipation of increased demand for services, the public education campaign launched in May 1988, and highlights of the scientific advances that make the program feasible and timely.
Abstract 19680: Cardiovascular Hypercontractility in Cantu Syndrome Results From Neurohumorally-induced Increase in Cardiomyocyte L-type Ca2+ Current
Authors: Mark D Levin, Gautam K Singh, Atilla Kovacs, Phyllis K Stein, Haixia Zhang, Maria S Remedi, Beth A Kozel, Dorthy K Grange, Colin G Nichols
Journal: Circulation (2014)

Cantu Syndrome (CS) is a rare multi-system disease characterized by hypertrichosis, skeletal abnormalities, and cardiovascular disease. Disease-causing gain of function (GOF) mutations have been identified in the genes encoding both the pore forming subunit (K IR  6.1, KCNJ8) and the accessory subunit (SUR2, ABCC9) of the K ATP  channel, but mechanisms by which K ATP  GOF mutations confer disease remain unclear. The purpose of this study was to characterize CS cardiovascular disease in a patient cohort and use engineered mouse models to explore how the cardiovascular features arise. Cardiovascular phenotyping demonstrated that CS patients have significantly diminished blood pressure, dilated LV, increased LV mass, and increased contractility (LV global strain (longitudinal)) as assessed by echo. Ambulatory ECG analysis demonstrated diminished heart rate variability, circadian abnormalities, and low vagal function. K ATP  currents recorded from cardiac [[Unable to Display Character: –]]specific K IR  6.1 gain of function ((cGOF), G343D) ventricular cardiomyocytes (VM) demonstrated diminished sensitivity to ATP inhibition. Smooth muscle cells (SMC) from vascular-specific K IR  6.1 GOF (vGOF) similarly showed diminished sensitivity to ATP inhibition. cGOF mice showed increased cardiac ejection fraction compared to control mice, while vGOF mice showed increased cardiac strain rate (SR rad-d) by echocardiogram. Neither cGOF, nor vGOF mice showed thickened LV wall dimensions when compared with control mice. Whole cell calcium current recordings from cGOF mouse vm showed markedly increased L-type Ca 2+  current (LTCCC) density that was comparable to that seen in WT vm treated with isoproterenol (iso). To increase K ATP  in both VM and SMC, slow release minoxidil (Min, a KATP channel opener) pellets, or placebo were implanted in WT mice for three weeks. Subsequent LTCCC recordings showed increased calcium current in MIN treated mice comparable to iso treated WT vm. Long-standing intracellular calcium excess is a well-described precipitant of cardiomyopathy and heart failure. Therefore, increased L-type calcium current found in K ATP  GOF models suggests a mechanistic link between increased K ATP  current and Cantu cardiac pathology.
A physiologically-based pharmacokinetic (PBPK) model of docetaxel in SCID mice bearing SKOV3 human ovarian cancer xenografts
Authors: Jeffry A. Florian, William C. Zamboni, Julie L. Eiseman, Mihaela C. Krasteva, Sandra Strychor, Erin Joseph, Robert A. Parise, Merrill J. Egorin, Robert S. Parker
Journal: Cancer Research (2006)

3102  Introduction: Docetaxel (DOC), a semisynthetic taxane, is active against a wide range of solid tumors. We previously reported tumor-specific retention of DOC in SKOV3 xenografts when compared to plasma and normal tissues (Strychor et al., AACR 2005 #4165). Because DOC disposition in tissue and tumor may play an important role in drug-related toxicity and efficacy, we developed a PBPK model to describe the time course of Doc in plasma, tumor, and normal tissues. Methods: DOC was administered IV at 10 mg/kg to female C.B.-17 SCID mice bearing SKOV3 human ovarian cancer xenografts. Mice (n = 3/time point) were euthanized, exsanguinated and dissected at 0.083, 0.25, 0.5, 1, 2, 4, 6, 7, 18, and 24 h after Doc administration. Doc concentrations in plasma, tumor, liver, kidney, spleen, brain, heart, and lung were determined by LC-MS. The PBPK model used first-order ordinary differential equations to describe inter-compartmental mass transport and estimate DOC concentrations in plasma, tumor, and normal tissue. Perfusion-limited tissues (liver, brain, tumor, lung, and spleen) were characterized with tissue subcompartments while diffusion-limited tissues (heart and kidney) were modeled using partition coefficients. Organ-specific blood flow values were fixed at values from the literature (US EPA / OHEA report, 1994) and organ volumes were fixed at mean post-exsanguination organ weights (n = 33). Parameter estimation and model structure selection was accomplished by minimizing the weighted sum of squared error between the model predictions and mean values of measured DOC concentrations for each organ. Results: In order to capture the measured dynamics, additional compartments (muscle and carcass) were included. Clearance was modeled as solely hepatic and estimated as 9.188 1/min. Vascular fractions for tumor, brain, liver, spleen, lung, and muscle were estimated as 0.016, 0.124, 0.975, 0.972, 0.967, and 0.060, respectively. Transfer rates from the vascular to the interstitial compartment for tumor, brain, liver, spleen, lung, and muscle were estimated as 0.129, 0.953, 8470.1, 0.031, 7.162, and 1.818 1/min, respectively. Likewise, transfer rates from the interstitial to the vascular compartment were found to be 0.001, 1.105, 48.00, 0.345, 4.173, and 0.320 1/min for tumor, brain, liver, spleen, lung, and muscle, respectively. Partition coefficients for the heart and kidney were estimated as 10.0 and 17.3, respectively. The model accurately captured DOC concentration versus time data for plasma, brain, tumor, liver, kidney, and heart. Model predictions for spleen and lung were less accurate. Conclusions: The PBPK model accurately describes Doc distribution in plasma, non-tumor, and tumor tissue. Support provided by Sanofi-Aventis Oncology and the Pittsburgh Tissue Engineering Initiative